This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, W.H. W. Articles by Hazen, S. L. Search for Related Content PubMed Articles by Tang, W.H. W. Articles by Hazen, S. L. Related Collections Related Articles

CLINICAL RESEARCH: CARDIOVASCULAR RISK

Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk

W.H. Wilson Tang, MD^_*,,_*, Zeneng Wang, PhD^_*, Leslie Cho, MD^_*,, Danielle M. Brennan, MS and Stanley L. Hazen, MD, PhD^_*,

^_* Center for Cardiovascular Diagnostics and Prevention, Department of Cell Biology, Lerner Research Institute, Cleveland, Ohio
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio

Manuscript received October 29, 2008; revised manuscript received February 6, 2009, accepted February 10, 2009.

^_* Reprint requests and correspondence: Dr. W. H. Wilson Tang, Heart and Vascular Institute, J3-4, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195 (Email: tangw{at}ccf.org).

Objectives: We hypothesized that an integrated assessment of arginine with its catabolic products might better predict cardiovascular risks than arginine levels alone.

Background: Arginine is the sole nitrogen source for nitric oxide (NO) synthesis. The major catabolic products of arginine are ornithine and citrulline.

Methods: Plasma levels of free arginine, ornithine, citrulline, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with liquid chromatography coupled with tandem mass spectrometry. We examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine + citrulline]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery disease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke) over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization.

Results: Patients with significantly obstructive CAD had significantly lower GABR (median [interquartile range]: 1.06 [0.75 to 1.31] vs. 1.27 [0.96 to 1.73], p < 0.001) and arginine levels [mean: 68 ± 20 µmol/l vs. 74 ± 24 µmol/l, p < 0.001) than those without significantly obstructive CAD. After adjusting for Framingham risk score, C-reactive protein, and renal function, lower GABR (but not arginine levels) and higher citrulline levels remained significantly associated with both the prevalence of significantly obstructive CAD (adjusted odds ratio: 3.93, p < 0.001, and 5.98, p < 0.001, respectively) and 3-year risk for the incidence of MACE (adjusted hazard ratio: 1.98, p = 0.025, and 2.40, p = 0.01, respectively) and remained significant after adjusting for ADMA.

Conclusions: GABR might serve as a more comprehensive concept of reduced NO synthetic capacity compared with systemic arginine levels. Diminished GABR and high citrulline levels are associated with both development of significantly obstructive atherosclerotic CAD and heightened long-term risk for MACE.

Key Words: arginine • coronary artery disease • nitric oxide • prognosis

Abbreviations and Acronyms   ADMA = asymmetric dimethylarginine   CAD = coronary artery disease   GABR = global arginine bioavailability ratio   hsCRP = high-sensitivity C-reactive protein   MACE = major adverse cardiovascular event(s)   MI = myocardial infarction   NO = nitric oxide

Related Articles

Arginine and Old MACE: Small Molecules in Atherogenesis Support the Concept of Coronary Artery Disease as a Complex Trait

Richard I. Levin
J. Am. Coll. Cardiol. 2009 53: 2068-2069. [Full Text] [PDF]

This article has been cited by other articles:

				Z. Wang, W. H. W. Tang, L. Cho, D. M. Brennan, and S. L. Hazen Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks: Potential Mechanisms Beyond Nitric Oxide Synthase Inhibition Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1383 - 1391. [Abstract] [Full Text] [PDF]

				R. I. Levin Arginine and Old MACE Small Molecules in Atherogenesis Support the Concept of Coronary Artery Disease as a Complex Trait. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2068 - 2069. [Full Text] [PDF]